Author: Meunier, Etienne ; Gestraud, Pierre ; Näser, Emmanuelle ; Watson, Sarah ; Kroemer, Guido ; Versini, Antoine ; Gandon, Vincent ; Puisieux, Alain ; Cañeque, Tatiana ; Wu, Ting-Di ; Cougoule, Céline ; Dawson, Mark A ; Robil, Cyril ; Pantoș, G Dan ; Müller, Sebastian ; Baron, Leeroy ; Gaillet, Christine ; Trottein, François ; Dingli, Florent ; Emam, Laila ; Bègue, Anne-Laure ; Servant, Nicolas ; Manel, Nicolas ; Péricat, David ; Mansart, Arnaud ; Sencio, Valentin ; Loew, Damarys ; Baulande, Sylvain ; Annane, Djillali ; Rodriguez, Raphaël ; Sindikubwabo, Fabien ; Solier, Stéphanie ; Durand, Sylvère ; Salmon, Hélène

AbstractInflammation is a complex physiological process triggered in response to harmful stimuli1. It involves cells of the immune system capable of clearing sources of injury and damaged tissues. Excessive inflammation can occur as a result of infection and is a hallmark of several diseases2–4. The molecular bases underlying inflammatory responses are not fully understood. Here we show that the cell surface glycoprotein CD44, which marks the acquisition of distinct cell phenotypes in the context of development, immunity and cancer progression, mediates the uptake of metals including copper. We identify a pool of chemically reactive copper(ii) in mitochondria of inflammatory macrophages that catalyses NAD(H) redox cycling by activating hydrogen peroxide. Maintenance of NAD+ enables metabolic and epigenetic programming towards the inflammatory state. Targeting mitochondrial copper(ii) with supformin (LCC-12), a rationally designed dimer of metformin, induces a reduction of the NAD(H) pool, leading to metabolic and epigenetic states that oppose macrophage activation. LCC-12 interferes with cell plasticity in other settings and reduces inflammation in mouse models of bacterial and viral infections. Our work highlights the central role of copper as a regulator of cell plasticity and unveils a therapeutic strategy based on metabolic reprogramming and the control of epigenetic cell states.

100 Deals associated with LCC-12

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Preclinical	CH	PSL Research University	26 Apr 2023
Inflammation	Preclinical	FR	Institut Curie	26 Apr 2023
Inflammation	Preclinical	FR	Centre National de la Recherche Scientifique	26 Apr 2023
Inflammation	Preclinical	FR	Institut National de la Santé et de la Recherche Médicale	26 Apr 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

LCC-12

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation